Pear Therapeutics (NASDAQ:PEAR) Stock Rating Reaffirmed by Chardan Capital

Pear Therapeutics (NASDAQ:PEAR – Get Rating)‘s stock had its “buy” rating reiterated by Chardan Capital in a report released on Monday, PriceTargets.com reports. Separately, Citigroup raised their target price on shares of Pear Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, May 17th. One equities research […]

Related Keywords

,Penserra Capital Management ,Roble Belko Company Inc ,Bergankdv Wealth Management ,Pear Therapeutics Company Profile Get Rating ,Magnus Financial Group ,York Mellon Corp ,Pear Therapeutics Inc ,Citigroup ,Pear Therapeutics ,Get Rating ,Chardan Capital ,Company Inc ,Capital Management ,New York Mellon Corp ,Therapeutics Company Profile ,Nasdaq Pear ,Pear ,Medical ,Reiterated Rating ,